Congratulations to Dr. Dan Stinchcomb, President & CEO and the entire team at InViragen (Ft. Collins) on their new partnership with the Pediatric Dengue Vaccine Initiative, to help develop and manufacture a dengue vaccine to be made widely available for the global prevention of dengue fever, the second most prevalent tropical disease after malaria.
Dengue fever is a mosquito-borne disease that is a potential threat to about half of the world’s population (3.5 billion people) living in tropical and subtropical countries. About 100 million people are infected with dengue every year. The disease is spreading to new parts of the globe each year (recent outbreaks in Paraguay and the Middle East). In addition, dengue affects countries such as Australia (Queensland) and the United States (Puerto Rico, Hawaii and the US-affiliated Pacific Islands). A substantial number of people traveling to or working in endemic regions are also infected each year.